

**Literaturverzeichnis zum Varia-Beitrag „Die HPV-Impfung“
von Dr. Marianne Röbl-Mathieu und Dr. Martin Tauscher
Bayerisches Ärzteblatt 9/2025, Seite 388 ff.**

1. Wieland U, Kreuter A (2022) Impfprävention HPV-assoziiierter Neoplasien. Forum 37:135–141
2. Kyrgiou M et al (2016) Adverse obstetric outcomes after local treatment for cervical preinvasive and early invasive disease according to cone depth: systematic review and meta-analysis. BMJ 354:i3633
3. Kraywinkel K, Takla A (2025) Zum Weltkrebstag 2025: HPV-bedingte Krebserkrankungen bei Männern – ein unterschätztes Risiko. Epid Bull 6:3-7
4. Hoes J et al. Review of long-term immunogenicity following HPV vaccination: Gaps in current knowledge. HUMAN VACCINES & IMMUNOTHERAPEUTICS 2022, VOL. 18, NO. 1, e1908059
5. Wei F et al (2024) Causal attribution of human papillomavirus genotypes to invasive cervical cancer worldwide: a systematic analysis of the global literature. The Lancet 404 (10451): 435 - 444
6. AG HPV der Ständigen Impfkommission (STIKO) (2018) Wissenschaftliche Begründung für die Empfehlung der HPV-Impfung für Jungen im Alter von 9 bis 14 Jahren. Epid Bull 26:233 – 250
7. Oberle D, Drechsel-Bäuerle U, Keller-Stanislawski B (2018) Sicherheit der Impfung gegen humane Papillomviren (HPV). Bulletin zur Arzneimittelsicherheit 3: 17 – 23
- Weekly epidemiological report (2017). Meeting of the Global Advisory Committee on Vaccine Safety, 7–8 June 2017. No 28 (92): 393–404
8. Weekly epidemiological report (2017). Meeting of the Global Advisory Committee on Vaccine Safety, 7–8 June 2017. No 28 (92): 393–404
9. Feiring B et al (2017) HPV vaccination and risk of chronic fatigue syndrome/myalgic encephalomyelitis: A nationwide register-based study from Norway. Vaccine 35: 4203–4212
10. Ward D et al (2018) A cluster analysis of serious adverse event reports after human papillomavirus (HPV) vaccination in Danish girls and young women, September 2009 to August 2017. Euro Surveill. 24(19):pii=1800380
11. Arnheim-Dahlström et al (2013) Autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: cohort study. BMJ 347:f5906
12. Hviid A, Myrup Thieson E (2021) Association Between Human Papillomavirus Vaccination and Primary Ovarian Insufficiency in a Nationwide Cohort. JAMA Network Open 4(8):e2120391
13. Drolet M et al (2019) Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis. [www.thelancet.com](http://dx.doi.org/10.1016/S0140-6736(19)30298-3). [http://dx.doi.org/10.1016/S0140-6736\(19\)30298-3](http://dx.doi.org/10.1016/S0140-6736(19)30298-3)
14. Dehlendorf C et al (2021) Real-World Effectiveness of Human Papillomavirus Vaccination Against Vulvovaginal High-Grade Precancerous Lesions and Cancers. JNCI J Natl Cancer Inst (2021) 113(7): djaa209
15. Baandrup L et al (2024) Human papillomavirus vaccination and anal high-grade precancerous lesions and cancer—a real-world effectiveness study. JNCI 116(2): 283–287
16. Röbl-Mathieu M (2024) HPV-Impfung: aktuelle Daten und Konzept der NaLI zur Förderung von Impfwissen und Impfbereitschaft. Berichtsband 8. Nationale Impfkongferenz 2024: S. 43 – 52

17. Lei et al. (2020) HPV vaccination and the Risk of Invasive Cervical Cancer. NEJM 383(14):1340–1348
18. Grieger P et al (2024) Initial evidence of a possible effect of HPV vaccination on cancer incidence in Germany—focus on cervical cancer. Dtsch Arztebl Int 121: 415–21
19. WHO global strategy to eliminate cervical cancer, www.who.int/publications/i/item/9789240014107
20. European Commission (2021) Europe's beating cancer plan. Communication from the commission to the European parliament and the council. https://health.ec.europa.eu/system/files/2022-02/eu_cancer-plan_en_0.pdf. Zugriff am 14.07.2025
21. Röbl-Mathieu M (2024) Serie Mädchensprechstunde M1. Teil 1: Beratungsinhalte und Hintergründe. Frauenarzt 65 (Nr. 9): 638-639